CMR FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Kimman, T. G.
Right arrow Articles by Klein, M. R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kimman, T. G.
Right arrow Articles by Klein, M. R.

Next Article 

Clinical Microbiology Reviews, July 2008, p. 403-425, Vol. 21, No. 3
0893-8512/08/$08.00+0     doi:10.1128/CMR.00014-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Evidence-Based Biosafety: a Review of the Principles and Effectiveness of Microbiological Containment Measures

Tjeerd G. Kimman,1* Eric Smit,2 and Michèl R. Klein1

Center for Infectious Disease Control,1 International Team, RIVM, National Institute of Public Health and the Environment, P.O. Box 1, 3720 BA Bilthoven, The Netherlands2

We examined the available evidence on the effectiveness of measures aimed at protecting humans and the environment against the risks of working with genetically modified microorganisms (GMOs) and with non-GMO pathogenic microorganisms. A few principles and methods underlie the current biosafety practice: risk assessment, biological containment, concentration and enclosure, exposure minimization, physical containment, and hazard minimization. Many of the current practices are based on experience and expert judgment. The effectiveness of biosafety measures may be evaluated at the level of single containment equipment items and procedures, at the level of the laboratory as a whole, or at the clinical-epidemiological level. Data on the containment effectiveness of equipment and laboratories are scarce and fragmented. Laboratory-acquired infections (LAIs) are therefore important for evaluating the effectiveness of biosafety. For the majority of LAIs there appears to be no direct cause, suggesting that failures of biosafety were not noticed or that containment may have been insufficient. The number of reported laboratory accidents associated with GMOs is substantially lower than that of those associated with non-GMOs. It is unknown to what extent specific measures contribute to the overall level of biosafety. We therefore recommend that the evidence base of biosafety practice be strengthened.


* Corresponding author. Mailing address: Center for Infectious Disease Control, RIVM-National Institute of Public Health and the Environment, P.O. Box 1, 3720 BA Bilthoven, The Netherlands. Phone: 31 (0)30 274 2330. Fax: 31 (0)6 46081730. E-mail: tg.kimman{at}rivm.nl


Clinical Microbiology Reviews, July 2008, p. 403-425, Vol. 21, No. 3
0893-8512/08/$08.00+0     doi:10.1128/CMR.00014-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Vaccine Immunol.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2008 by the American Society for Microbiology. All rights reserved.